 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Exenatide or Insulin Glargine for Suboptimally Controlled Diabetes?
18 October 2005 | Volume 143 Issue 8 | Page I-30
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes. A Randomized Trial." It is in the 18 October 2005 issue of Annals of Internal Medicine (volume 143, pages 559-569). The authors are R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel, and R.G. Brodows, for the GWAA Study Group.
What is the problem and what is known about it so far?
Patients with type 2 diabetes have impaired ability to store energy from food and high blood sugar levels. Over time, they may experience complications like kidney disease, heart disease, blindness, and nerve damage (neuropathy). To help avoid some of these problems, doctors try to control patients' blood sugar levels with diet and diabetes drugs. Diabetes drugs include glucose-lowering pills, such as metformin and sulfonylurea drugs. Although these pills help, many patients do not achieve or cannot sustain good glucose control with pills alone. Options for these patients are to add drugs that are given as injections, such as insulin glargine (a long-acting insulin) or exenatide (a new incretin mimetic drug). Because exenatide is a new drug, however, we know relatively little about its benefits and harms compared with insulin.
Why did the researchers do this particular study?
To compare the benefits and harms of exenatide and insulin glargine injections in patients with type 2 diabetes who were already taking 2 oral blood glucose–lowering drugs.
Who was studied?
551 adults with type 2 diabetes who had suboptimal glucose control despite taking metformin and a sulfonylurea.
How was the study done?
The researchers recruited patients with type 2 diabetes from 82 sites in 13 countries. All patients were taking maximally effective doses of metformin and a sulfonylurea for at least 3 months and had hemoglobin A1c levels ranging from 7% to 10%. They were randomly assigned to receive either exenatide injections before morning and evening meals or insulin glargine injections at bedtime. Exenatide doses were 5 µg twice daily for 4 weeks, then 10 µg twice daily. Insulin glargine doses began at 10 units daily and were adjusted in 2-U increments every 3 days as needed to try to reach a fasting blood glucose target of 100 mg/dL. During a 26-week follow-up period, patients were asked regularly about adverse effects, were weighed, and had multiple blood tests to assess glucose control.
What did the researchers find?
Both exenatide and insulin glargine improved overall glucose control. Both reduced hemoglobin A1c level by about 1% from baseline levels that had averaged about 8.2%. Patients in the exenatide group lost about 5 pounds, and patients in the insulin glargine group gained about 4 pounds. Patients reported more adverse effects with exenatide than with insulin glargine, including nausea (57.1% compared with 8.6%), vomiting (17.4% compared with 3.7%), and diarrhea (8.5% compared with 3.0%).
What were the limitations of the study?
The patients and their doctors knew which drugs the patients were receiving. Of the patients receiving exenatide, 19.4% stopped the injections (withdrew from the study) compared with 9.7% of the patients receiving insulin. Only 21.6% and 8.6% of the patients taking insulin and exenatide, respectively, achieved target fasting glucose levels of 100 mg/dL.
What are the implications of the study?
Both exenatide and insulin glargine can improve glucose control in patients with type 2 diabetes whose disease is not controlled despite taking 2 oral blood glucose–lowering drugs. Exenatide is more likely than insulin glargine to cause gastrointestinal adverse effects.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. W. Chia and J. M. Egan Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3703 - 3716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kidambi and S. B. Patel Diabetes Mellitus: Considerations for Dentistry J Am Dent Assoc, October 1, 2008; 139(suppl_5): 8S - 18S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Three new drugs for type 2 diabetes DTB, July 1, 2008; 46(7): 49 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F Van Gaal, S. W Gutkin, and M. A Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cure, A. Pileggi, R. Alejandro, S. R. Ahmad, J. Swann, G. Bloomgren, D. Braun, and O. Kolterman Exenatide and Rare Adverse Events N. Engl. J. Med., May 1, 2008; 358(18): 1969 - 1972. [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Martin Beyond Glycemic Control: The Effects of Incretin Hormones in Type 2 Diabetes The Diabetes Educator, May 1, 2008; 34(Supplement_3): 66S - 72S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Monnier and C. Colette Glycemic Variability: Should we and can we prevent it? Diabetes Care, February 1, 2008; 31(Supplement_2): S150 - S154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Dixon, P. E. O'Brien, J. Playfair, L. Chapman, L. M. Schachter, S. Skinner, J. Proietto, M. Bailey, and M. Anderson Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes: A Randomized Controlled Trial JAMA, January 23, 2008; 299(3): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Management of Type 2 Diabetes N. Engl. J. Med., January 17, 2008; 358(3): 293 - 297. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Davis, D. Johns, D. Maggs, H. Xu, J. H. Northrup, and R. G. Brodows Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents Diabetes Care, November 1, 2007; 30(11): 2767 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Tschop and E. Ravussin Peptide YY: obesity's cause and cure? Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1131 - E1133. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Heine, R. Brodows, E. G. Maderazo, D. Tarsy, and M. Camilleri Diabetic Gastroparesis N. Engl. J. Med., July 26, 2007; 357(4): 418 - 420. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Amori, J. Lau, and A. G. Pittas Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis JAMA, July 11, 2007; 298(2): 194 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hollander Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes Diabetes Spectr, July 1, 2007; 20(3): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
|
|
D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Andrews, A. E. Bharucha, M. Camilleri, P. A. Low, B. Seide, D. Burton, K. Baxter, and A. R. Zinsmeister Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1359 - G1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zinman, B. J. Hoogwerf, S. Duran Garcia, D. R. Milton, J. M. Giaconia, D. D. Kim, M. E. Trautmann, and R. G. Brodows The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial Ann Intern Med, April 3, 2007; 146(7): 477 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kruger Tying It All Together: Matching Insulin Regimens to Individual Patient Needs The Diabetes Educator, April 1, 2007; 33(Supplement_4): 91S - 95S. [Full Text] [PDF]
|
|
|
|
|
|
M. Camilleri Diabetic Gastroparesis N. Engl. J. Med., February 22, 2007; 356(8): 820 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 J. de Heer and J. J. Holst Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1 Diabetes, February 1, 2007; 56(2): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Heine, M Diamant, J-C Mbanya, and D M Nathan Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ, December 9, 2006; 333(7580): 1200 - 1204. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Yoo, D. M. Triller, and D. J. Yoo Exenatide: A New Option for the Treatment of Type 2 Diabetes Ann. Pharmacother., October 1, 2006; 40(10): 1777 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
|
|
A. B. King, G. Wolfe, and S. Healy Clinical Observations of Exenatide Treatment Diabetes Care, August 1, 2006; 29(8): 1984 - 1984. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Beckley Exenatide Rivals Glargine for A1C Control DOC News, December 1, 2005; 2(12): 7 - 7. [Full Text]
|
|
|
|
|
|
Endocrinology & Metabolism News, December 2005 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 17a - 17a. [Full Text] [PDF]
|
|
|
|
 |
|
 New Treatments for Uncontrolled Diabetes Journal Watch (General), October 25, 2005; 2005(1025): 1 - 1. [Full Text]
|
|
|
|
|
|
R. J. Comi Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma Ann Intern Med, October 18, 2005; 143(8): 609 - 610. [Full Text] [PDF]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
